Chesterbrook, PA-based AmerisourceBergen Corporation is one of the world’s largest pharmaceutical services companies, which focuses on providing drug distribution and related services to reduce healthcare costs and improve patient outcomes. AmerisourceBergen serves healthcare providers and pharmaceutical manufacturers in the pharmaceutical supply channel.
The company has been actively pursuing acquisitions to strengthen its core areas and diversify. The MWI Veterinary acquisition diversified its existing pharmaceutical distribution & services businesses into the attractive animal health market, while the PharMedium buyout added to its ability to provide market-leading services and solutions to health system customers. The company entered into a strategic agreement with Walgreen Boots Alliance in 2013 and extended the term of its 10-year pharmaceutical distribution agreement by three years.
AmerisourceBergen’s track record has been mixed with the company comfortably beating estimates in three of the last four quarters with an average positive surprise of 2.7%. Estimates for fiscal 2016 have been more or less static in the last 30 days.
Currently, AmerisourceBergen has a Zacks Rank #2 (Buy) but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: AmerisourceBergen topped earnings in the reported quarter. Our consensus called for EPS of $1.26, and the company reported EPS of $1.37.
Revenue: AmerisourceBergen posted revenues of $36.9 billion in the reported quarter, slightly above the consensus estimate of $36.6 billion.
Key Stats: The acquisitions of MWI Veterinary Supply and PharMEDium have boosted performance. AmerisourceBergen now expects earnings per share in the range of$5.52 – $5.57.
Check back later for our full write up on this AmerisourceBergen earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Chesterbrook, PA-based AmerisourceBergen Corporation is one of the world’s largest pharmaceutical services companies, which focuses on providing drug distribution and related services to reduce healthcare costs and improve patient outcomes. AmerisourceBergen serves healthcare providers and pharmaceutical manufacturers in the pharmaceutical supply channel.
The company has been actively pursuing acquisitions to strengthen its core areas and diversify. The MWI Veterinary acquisition diversified its existing pharmaceutical distribution & services businesses into the attractive animal health market, while the PharMedium buyout added to its ability to provide market-leading services and solutions to health system customers. The company entered into a strategic agreement with Walgreen Boots Alliance in 2013 and extended the term of its 10-year pharmaceutical distribution agreement by three years.
AmerisourceBergen’s track record has been mixed with the company comfortably beating estimates in three of the last four quarters with an average positive surprise of 2.7%. Estimates for fiscal 2016 have been more or less static in the last 30 days.
Currently, AmerisourceBergen has a Zacks Rank #2 (Buy) but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: AmerisourceBergen topped earnings in the reported quarter. Our consensus called for EPS of $1.26, and the company reported EPS of $1.37.
Revenue: AmerisourceBergen posted revenues of $36.9 billion in the reported quarter, slightly above the consensus estimate of $36.6 billion.
Key Stats: The acquisitions of MWI Veterinary Supply and PharMEDium have boosted performance. AmerisourceBergen now expects earnings per share in the range of$5.52 – $5.57.
Check back later for our full write up on this AmerisourceBergen earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>